tiprankstipranks
Advertisement
Advertisement
Hutchmed Expands Oncology Pipeline With New First‑in‑Human Solid Tumor Trial
PremiumCompany AnnouncementsHutchmed Expands Oncology Pipeline With New First‑in‑Human Solid Tumor Trial
3M ago
Hutchmed price target lowered to $20 from $21 at BofA
Premium
The Fly
Hutchmed price target lowered to $20 from $21 at BofA
3M ago
Hutchmed discontinues all active tazemetostat clinical trials
Premium
The Fly
Hutchmed discontinues all active tazemetostat clinical trials
3M ago
Hutchmed initiates Phase III stage of Phase II/III trial
PremiumThe FlyHutchmed initiates Phase III stage of Phase II/III trial
5M ago
Hutchmed initiates Phase III stage of Phase II/III trial
Premium
The Fly
Hutchmed initiates Phase III stage of Phase II/III trial
5M ago
Hutchmed announces savolitinib new drug application acceptance in China
Premium
The Fly
Hutchmed announces savolitinib new drug application acceptance in China
5M ago
Hutchmed’s HMPL-506 Study: A Potential Game-Changer in Hematological Malignancies
PremiumCompany AnnouncementsHutchmed’s HMPL-506 Study: A Potential Game-Changer in Hematological Malignancies
8M ago
Hutchmed’s Promising Study in Metastatic Pancreatic Cancer: A Potential Game Changer
Premium
Company Announcements
Hutchmed’s Promising Study in Metastatic Pancreatic Cancer: A Potential Game Changer
8M ago
Hutchmed’s Phase III Study on HMPL-306: A Potential Game-Changer for AML Treatment
Premium
Company Announcements
Hutchmed’s Phase III Study on HMPL-306: A Potential Game-Changer for AML Treatment
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100